Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates.
David-Dan NguyenNeil BarberMo BidairPeter J GillingPaul AndersonKevin C ZornGopal BadlaniMitch HumphreysSteven KaplanRonald KaufmanAlan SoRyan PatersonLarry GoldenbergDean EltermanMihir DesaiJim LingemanClaus RoehrbornNaeem BhojaniPublished in: BJU international (2019)
Aquablation clinically normalises outcomes between patients with 30-80 mL prostates and patients with 80-150 mL prostates treated for LUTS/BPH, with an expected increase in the risk of complications in larger prostates. Long-term outcomes of procedure durability are needed.
Keyphrases
- benign prostatic hyperplasia
- lower urinary tract symptoms
- clinical trial
- study protocol
- ultrasound guided
- risk factors
- minimally invasive
- phase iii
- phase ii
- randomized controlled trial
- prostate cancer
- adipose tissue
- metabolic syndrome
- radiofrequency ablation
- skeletal muscle
- newly diagnosed
- catheter ablation
- double blind